The New Drug Application for SD-809 (deutetrabenazine) has been accepted by the US Food and Drug Administration, according to the drug’s developer, Israel-based generics giant Teva Pharmaceutical Industries. 13 August 2015
Following an assessment of a dossier from Danish CNS specialist Lundbeck for its drug Brintellix (vortioxetine), the German Institute for Quality and Efficiency in Health Care (IQWiG) has concluded that no added benefit for the product in the treatment of depression can be derived based on the evaluable data. 12 August 2015
The US Food and Drug Administration has approved Swedish drug developer Orexo’s Zubsolv (buprenorphine/naloxone CIII sublingual tablet) for induction of buprenorphine maintenance therapy in patients with opioid dependence. 12 August 2015
Danish CNS drug specialist Lundbeck on Tuesday with Takeda Pharmaceutical (TYO: 4502) said the US Food and Drug Administration has accepted a supplemental New Drug Application for antidepressant Brintellix (vortioxetine). 11 August 2015
Edison Research on Monday said it is encouraged by recent prescription data for Swedish drug developer Orexo’s dropped Zubsolv (buprenorphine/naloxone CIII sublingual tablet) after the insurer CVS/ caremark dropper it from its list of prescription drug insurance. 10 August 2015
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson's disease, scientists from the University of Sheffield have discovered, reports EurekAlert. 10 August 2015
Danish CNS specialist Lundbeck has joined the Global Alzheimer’s Platform (GAP) to help accelerate the development of new treatments for Alzheimer’s disease. 8 August 2015
US biotech firm ACADIA Pharmaceuticals has announced the publication of new data from its ongoing open-label safety extension study, the -015 Study, with Nuplazid (pimavanserin) in patients with Parkinson’s disease psychosis (PDP) in the online issue of the Journal of the American Medical Directors Association. 7 August 2015
Australian Minister for Health Sussan Ley today launched a three-pronged approach to support and promote dementia research in the search of new treatments, models of care and ways of preventing the debilitating disease 7 August 2015
UK biopharma company GW Pharmaceuticals has been granted Fast Track designation by the US Food and Drug Administration for its proprietary intravenous form of cannabidiol to treat neonatal hypoxic-ischemic encephalopathy (NHIE). 6 August 2015
The UK Competition and Markets Authority (CMA) has today issued a statement of objections to the pharmaceutical suppliers Pfizer and Flynn Pharma alleging that they have breached competition law. 6 August 2015
The US Food and Drug Administration yesterday issued a warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS). 5 August 2015
Addex Therapeutics on Wednesday said it sees sales of up to $900 million from its drug candidate to treat involuntary movements induced by prolonged intake of treatment of levodopa in Parkinson's patients. 5 August 2015
US privately-held specialty company Aprecia Pharmaceuticals says that the US Food and Drug Administration has approved Spritam (levetiracetam). 4 August 2015
US pharma giant Pfizer has acquired the exclusive commercialization rights in the USA to glatiramer acetate, a potential generic version of the originator Israel-based Teva Pharmaceutical Industries’ blockbuster drug Copaxone. 3 August 2015
Drugs commonly used to treat dementia could result in harmful weight loss, according to UC San Francisco researchers, saying that clinicians need to account for this risk when prescribing these drugs to older adults. 3 August 2015
The US Food and Drug Administration is warning health care professionals and patients that reports of confusion between the antidepressant Brintellix (vortioxetine) and anti-blood clotting medication Brilinta (ticagrelor) have resulted in the wrong medication being prescribed or dispensed. 31 July 2015
Vitae Pharmaceuticals today announced that German family-owned pharma major Boehringer Ingelheim is ending the parties' collaboration and license agreement for orally-active beta secretase (BACE) inhibitors. 27 July 2015
Ireland-incorporated Allergan on Sunday revealed its intention to acquire USA-based privately-held Naurex, amid speculation that it was also about to divest its generics business. 26 July 2015
In a second major deal for the Indian drugmaker within two days, Lupin said on Friday it has entered into a strategic asset purchase agreement with Temmler Pharma, a part of the Aenova Group. 26 July 2015
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024